After two attempts to get out of a whistleblower case, Pfizer is still on the hook for claims it illegally marketed an anti-fungal medication, Vfend, for off-label use.

U.S. District Judge Barclay Surrick of the Eastern District of Pennsylvania denied Pfizer’s motion to dismiss relators’ Catherine Brown and Bernard Vezeau’s false claims qui tam case against the company.